期刊的影响因子--文章列表

期刊文章列表
HaoXu，YishengPan，NingZhang（Division of General Surgery,Peking University,Peking University First Hospital；Translational Cancer Research Center,Peking University,Peking University First Hospital）.A breakthrough in liver regeneration for treatment of liver cancer[J].Cancer Biology & Medicine,2021,第3期 Diya Liu， Lin Fang（Department of Thyroid and Breast Diseases,Shanghai Tenth People’s Hospital）.Current research on circular RNAs and their potential clinical implications in breast cancer[J].Cancer Biology & Medicine,2021,第3期 YongqiaoHe，DaweiYang，TingZhou，WenqiongXue，JiangboZhang，FangfangLi，FangWang，TongminWang，ZiyiWu，YingLiao，MeiqiZheng，ChangmiDeng，DanhuaLi，YijingJia，LeileiYuan，WenliZhang，WeihuaJia（Department of Radiation Oncology,Affiliated Cancer Hospital & Institute of Guangzhou Medical University；State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine，Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy,Sun Yat-sen University Cancer Center；School of Public Health,Sun Yat-sen University；Department of Medical Oncology,Sun Yat-sen University Cancer Center）.Epstein-Barr virus DNA loads in the peripheral blood cells predict the survival of locoregionally-advanced nasopharyngeal carcinoma patients[J].Cancer Biology & Medicine,2021,第3期 RosariaA.Fontanella，SilviaSideri，ChiaraDiStefano，AngiolinaCatizone，SilviaDiAgostino，DanielaF.Angelini，GisellaGuerrera，LucaBattistini，GiuliaBattafarano，AndreaDelFattore，AntonioFrancescoCampese，FabrizioPadula，PaolaDeCesaris，AntonioFilippini，AnnaRiccioli（Department of Anatomy,Histology,Forensic Medicine and Orthopaedics,Unit of Histology and Medical Embryology，Sapienza University；Department of Health Sciences School of Medicine – "Magna Graecia" University of Catanzaro；IRCCS Fondazione Santa Lucia；Bone Physiopathology Research Unit，Genetics and Rare Diseases Research Division,Bambino Gesù Children’s Hospital，IRCCS；Department of Molecular Medicine,Sapienza University；Department of Life,Health and Environmental Sciences，University of L’Aquila）.CD44v8-10 is a marker for malignant traits and a potential driver of bone metastasis in a subpopulation of prostate cancer cells[J].Cancer Biology & Medicine,2021,第3期 AnjieZhu，PengYuan，NanlinHu，MingzhouLi，WenmiaoWang，XueWang，JianYue，JiayuWang，YangLuo，FeiMa，PinZhang，QingLi，BingheXu，ShanboCao，GiuseppeLippi，YoichiNaito，MohammedA.Osman，GustavoN.Marta，GianlucaFranceschini，ArmandoOrlandi（Department of Medical Oncology,National Cancer Center，National Clinical Research Center for Cancer，Cancer Hospital，Chinese Academy of Medical Sciences and Peking Union Medical College；Key Laboratory of Carcinogenesis and Translational Research （Ministry of Education，Beijing）,Department of Breast Oncology,Peking University Cancer Hospital & Institute；Department of VIP Medical Services,National Cancer Center，National Clinical Research Center for Cancer，Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College；Department of Pathology,National Cancer Center，National Clinical Research Center for Cancer，Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College；Acorn Med Biotechnology Co.,Ltd.；Section of Clinical Biochemistry,University Hospital of Verona；Department of Breast and Medical Oncology,National Cancer Center Hospital East；Clinical Oncology,General Organization for Teaching Hospitals）.Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA[J].Cancer Biology & Medicine,2021,第3期 MeitingChen，ZhaoWang，XiaojieFang，YuyiYao，QuanguangRen，ZegengChen，YingTian，FeiPan，XiaoqianLi，ZhimingLi，QingqingCai，HeHuang，TongyuLin（Department of Medical Oncology,Sun Yat-sen University Cancer Center,State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine；Senior Ward，Phase Ⅰ Clinical Trial Ward,Sichuan Cancer Hospital & Institute,Sichuan Cancer Center,School of Medicine,University of Electronic Science and Technology of China）.Modified R-CODOX-M/IVAC chemotherapy regimens in Chinese patients with untreated sporadic Burkitt lymphoma[J].Cancer Biology & Medicine,2021,第3期 ChenxiLi，YongmeiZhou，YiwenDeng，XueminShen，LinjunShi，WeiLiu（Department of Oral Mucosal Diseases,Shanghai Ninth People’s Hospital,Shanghai Jiao Tong University School of Medicine，College of Stomatology,Shanghai Jiao Tong University，National Center for Stomatology,National Clinical Research Center for Oral Diseases,Shanghai Key Laboratory of Stomatology；Department of Oral and Maxillofacial-Head and Neck Oncology,Shanghai Ninth People’s Hospital,Shanghai Jiao Tong University School of Medicine）.Development and validation of a risk model for noninvasive detection of cancer in oral potentially malignant disorders using DNA image cytometry[J].Cancer Biology & Medicine,2021,第3期 TaoChen，FeiWang，ShupeiWei，YingjieNie，XiaotaoZheng，YuDeng，XubinZhu，YuezhenDeng，NanshanZhong，ChengzhiZhou（State Key Laboratory of Respiratory Disease,National Clinical Research Center for Respiratory Disease,Guangzhou Institute of Respiratory Health,the First Affiliated Hospital of Guangzhou Medical University；NHC Key Laboratory of Pulmonary Immunological Diseases,Clinical Research Lab Center,Guizhou Provincial People’s Hospital；Longgang Central Hospital of Shenzhen,Affiliated Shenzhen Longgang Central Hospital of Zunyi Medical College；Center for Molecular Medicine,Xiangya Hospital,Central South University）.FGFR/RACK1 interacts with MDM2, promotes P53 degradation, and inhibits cell senescence in lung squamous cell carcinoma[J].Cancer Biology & Medicine,2021,第3期 Brandon M. Bordeau， Joseph P. Balthasar（Department of Pharmaceutical Science,University at Buffalo）.Strategies to enhance monoclonal antibody uptake and distribution in solid tumors[J].Cancer Biology & Medicine,2021,第3期 GuangboKang，MinHu，HeRen，JiewenWang，XinCheng，RuoweiLi，BoYuan，YasmineBalan，ZixuanBai，HeHuang（Department of Biochemical Engineering,School of Chemical Engineering & Technology,Tianjin University；Key Laboratory of Systems Bioengineering （Ministry of Education）,Tianjin University；Department of Gastroenterology,Center of Tumor Immunology and Cytotherapy,Medical Research Center of The Affiliated Hospital of Qingdao University；Department of Chemical and Biological Engineering,University of Ottawa）.VHH212 nanobody targeting the hypoxia-inducible factor 1α suppresses angiogenesis and potentiates gemcitabine therapy in pancreatic cancer in vivo[J].Cancer Biology & Medicine,2021,第3期 TianqingChu，JunLu，MinghongBi，HelongZhang，WuZhuang，YanYu，JianhuaShi，ZhendongChen，XiaochunZhang，QisenGuo，QuanLiu，HuijuanWu，JianFang，YiHu，XiuwenWang，CuicuiHan（Department of Pulmonary Medicine,Shanghai Chest Hospital,Shanghai Jiao Tong University；Department of Oncology,The First Affiliated Hospital of Bengbu Medical College；Department of Oncology,Tangdu Hospital,Air Force Medical University of PLA；Department of Medical Thoracic Oncology,Fujian Cancer Hospital,Fujian Medical University Cancer Hospital；Department of Oncology,Harbin Medical University Cancer Hospital；Department of Oncology,Linyi Cancer Hospital；Department of Oncology,The Second Hospital of Anhui Medical University；Department of Oncology,The Affiliated Hospital of Qingdao University；Department of Internal Medicine,Shandong Cancer Hospital Affiliated to Shandong University；Department of Oncology,Affiliated Hospital of Jiang Nan University；Department of Internal Medicine,Henan Province Tumor Hospital,Zhengzhou University；Department of Thoracic Oncology Ⅱ,Peking University Cancer Hospital and Institute；Department of Oncology,Chinese PLA General Hospital）.Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial[J].Cancer Biology & Medicine,2021,第3期 EvgeniyaV.Dolgova，OlegM.Andrushkevich，PolinaE.Kisaretova，AnastasiaS.Proskurina，GenrikhS.Ritter，TatyanaD.Dubatolova，MargaritaV.Romanenko，OlegS.Taranov，YaroslavR.Efremov，EvgeniyL.Zavyalov，AlexandrV.Romaschenko，SergeyV.Mishinov，SvetlanaS.Kirikovich，EvgeniyV.Levites，EkaterinaA.Potter，AlexandrA.Ostanin，ElenaR.Chernykh，StanislavYu.Roshchin，AnatoliyV.Bervitskiy，GalinaI.Moysak，JamilA.Rzaev，SergeyS.Bogachev（Institute of Cytology and Genetics SB RAS；A.I.Evdokimov Moscow State University of Medicine and Dentistry；Institute of Molecular and Cellular Biology；Novosibirsk State University；The State Research Center of Virology and Biotechnology "Vector"；First Department of Neurosurgery,Ya.L.Tsivian Novosibirsk Research Institute of Traumatology and Orthopaedics；Institute of Fundamental and Clinical immunology；Sklifosovsky Research Institute of Emergency Medicine；Federal Center of Neurosurgery）.Efficacy of the new therapeutic approach in curing malignant neoplasms on the model of human glioblastoma[J].Cancer Biology & Medicine,2021,第3期 WinnieYeo，LeungLi，ThomasKHLau，KwaiTLai，VickyTCChan，KwanHWong，ChristopherCHYip，ElizabethPang，MaggieCheung，VivianChan，CarolCHKwok，JoyceJSSuen，FrankieKFMo（Department of Clinical Oncology,Prince of Wales Hospital,Faculty of Medicine,Hong Kong Cancer Institute；State Key Laboratory of Translational Oncology,The Chinese University of Hong Kong；Department of Clinical Oncology,Princess Margaret Hospital）.Identification of optimal contemporary antiemetic prophylaxis for doxorubicin-cyclophosphamide chemotherapy in Chinese cancer patients: post-hoc analysis of 3 prospective studies[J].Cancer Biology & Medicine,2021,第3期 ChengmingLiu，SihuiWang，SufeiZheng，XinfengWang，JianbinHuang，YuanyuanLei，ShuangshuangMao，XiaoliFeng，NanSun，JieHe（Department of Thoracic Surgery,National Cancer Center，National Clinical Research Center for Cancer，Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College；Department of Pathology,National Cancer Center，National Clinical Research Center for Cancer，Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College）.A novel recurrence-associated metabolic prognostic model for risk stratification and therapeutic response prediction in patients with stage I lung adenocarcinoma[J].Cancer Biology & Medicine,2021,第3期 Rui Li^1,2，Zhimin Chen¹，Zhifei Dai²，Yingjie Yu³（College of Life Science and Technology，Beijing University of Chemical Technology；Department of Biomedical Engineering，College of Engineering，Peking University；Institute of Translational Medicine，The First Affiliated Hospital of Shenzhen University，Shenzhen Second People’s Hospital）.Nanotechnology assisted photo- and sonodynamic therapy for overcoming drug resistance[J].Cancer Biology & Medicine,2021,第2期 Jiaqi Wang^1,2，Yi Zhang¹，Lianyu Liu^1,2，Ting Yang¹，Jun Song^1,2（Department of General Surgery，The Affiliated Hospital of Xuzhou Medical University；Institute of Digestive Diseases of Xuzhou Medical University）.Circular RNAs: new biomarkers of chemoresistance in cancer[J].Cancer Biology & Medicine,2021,第2期 Mingwei Chen¹，Xuedong Wei¹，Xiu Shi²，Le Lu¹，Guangbo Zhang^1,3，Yuhua Huang¹，Jianquan Hou¹（Department of Urology，The First Affiliated Hospital of Soochow University；Department of Obstetrics and Gynecology，The First Affiliated Hospital of Soochow University；Jiangsu Institute of Clinical Immunology，The First Affiliated Hospital of Soochow University，Jiangsu Key Laboratory of Clinical Immunology，Soochow University，Jiangsu Key Laboratory of Gastrointestinal Tumor Immunology）.LncRNA HIF1A-AS2 accelerates malignant phenotypes of renal carcinoma by modulating miR-30a-5p/SOX4 axis as a ceRNA[J].Cancer Biology & Medicine,2021,第2期 Xianxian Wu¹，Hongdian Zhang¹，Zhilin Sui¹，Yang Wang²，Zhentao Yu¹（Departments of Esophageal Cancer，Tianjin Medical University Cancer Institute and Hospital，National Clinical Research Center for Cancer，Key Laboratory of Cancer Prevention and Therapy，Tianjin，Tianjin’s Clinical Research Center for Cancer；Department of Immunology，Tianjin Medical University Cancer Institute and Hospital，National Clinical Research Center for Cancer，Key Laboratory of Cancer Prevention and Therapy，Tianjin，Tianjin’s Clinical Research Center for Cancer）.The biological role of the CXCL12/CXCR4 axis in esophageal squamous cell carcinoma[J].Cancer Biology & Medicine,2021,第2期 Xueping Tao^1,2，Yongfu Shao²，Jianing Yan^1,2，Liyang Yang^1,2，Qihua Ye^1,2，Qingling Wang^1,2，Rongdan Lu²，Junming Guo^1,2（Department of Biochemistry and Molecular Biology and Zhejiang Key Laboratory of Pathophysiology，Ningbo University School of Medicine；Department of Gastroenterology，the Affiliated Hospital of Medical School of Ningbo University）.Biological roles and potential clinical values of circular RNAs in gastrointestinal malignancies[J].Cancer Biology & Medicine,2021,第2期 Xubo Zhao¹，Jie Bai¹，Wenjing Yang²（Green Catalysis Center and College of Chemistry，Zhengzhou University；Department of Anesthesiology，The First Affiliated Hospital of Zhengzhou University）.Stimuli-responsive nanocarriers for therapeutic applications in cancer[J].Cancer Biology & Medicine,2021,第2期 Ying Xue¹，Yuting Gao¹，Fanling Meng^1,2，Liang Luo^1,2,3（National Engineering Research Center for Nanomedicine，College of Life Science and Technology，Huazhong University of Science and Technology；Hubei Key Laboratory of Bioinorganic Chemistry and Materia Medica，School of Chemistry and Chemical Engineering，Huazhong University of Science and Technology；Research Institute of Huazhong University of Science and Technology in Shenzhen）.Recent progress of nanotechnology-based theranostic systems in cancer treatments[J].Cancer Biology & Medicine,2021,第2期 Huizhi Sun^1,2，Danfang Zhang²，Chongbiao Huang¹，Yuhong Guo¹，Zhao Yang²，Nan Yao²，Xueyi Dong²，Runfen Cheng¹，Nan Zhao²，Jie Meng²，Baocun Sun²，Jihui Hao¹（Tianjin Medical University Cancer Institute and Hospital，National Clinical Research Center for Cancer，Key Laboratory of Cancer Prevention and Therapy，Tianjin，Tianjin’s Clinical Research Center for Cancer；Department of Pathology，School of Basic Medical Science，Tianjin Medical University）.Hypoxic microenvironment induced spatial transcriptome changes in pancreatic cancer[J].Cancer Biology & Medicine,2021,第2期 Yawen Song¹，Hui Sun¹，Kailiang Wu¹，Jianke Lyu¹，Jingyue Zhang¹，Feng Gu¹，Yongjie Ma¹，Beibei Shen¹，Chijuan Wang¹，Xiaojiao Chen¹，Jing Xu¹，Weidong Li¹，Fangfang Liu¹，Li Fu¹（Department of Breast Cancer Pathology and Research Laboratory，Tianjin Medical University Cancer Institute and Hospital，National Clinical Research Center for Cancer，Key Laboratory of Cancer Prevention and Therapy，Tianjin，Tianjin’s Clinical Research Center for Cancer；Key Laboratory of Breast Cancer Prevention and Therapy，Tianjin Medical University，Ministry of Education；Breast Cancer Innovation Team of the Ministry of Education；State Key Laboratory of Breast Cancer Research）.sLe^x expression in invasive micropapillary breast carcinoma is associated with poor prognosis and can be combined with MUC1/EMA as a supplementary diagnostic indicator[J].Cancer Biology & Medicine,2021,第2期 Yan Song¹，Juxiang Xiao²，Wentao Fang³，Ping Lu⁴，Qingxia Fan⁵，Yongqian Shu⁶，Jifeng Feng⁷，Shu Zhang⁸，Yi Ba⁹，Yang Zhao¹⁰，Ying Liu¹¹，Chunmei Bai¹²，Yuxian Bai¹³，Yong Tang¹⁴，Jie He¹⁵，Jing Huang¹（Department of Medical Oncology，National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital，Chinese Academy of Medical Sciences and Peking Union Medical College；Department of Medical Oncology，First Hospital of Xi’an Jiaotong University；Department of Thoracic Surgery，Shanghai Chest Hospital，Shanghai Jiao Tong University；Department of Medical Oncology，First Affiliated Hospital of Xinxiang Medical University；Department of Oncology，The First Affiliated Hospital of Zhengzhou University；Department of Oncology，The First Affiliated Hospital of Nanjing Medical University；Department of Medical Oncology，Jiangsu Cancer Hospital；Department of Medical Oncology，Shandong Cancer Hospital；Department of Medical Oncology，Tianjin Medical University Cancer Institute and Hospital，National Clinical Research Center for Cancer，Key Laboratory of Cancer Prevention and Therapy，Tianjin，Tianjin’s Clinical Research Center for Cancer；Department of Biostatistics，School of Public Health，Nanjing Medical University；Department of Medical Oncology，Henan Cancer Hospital；Department of Oncology，Peking Union Medical College Hospital，Chinese Academy of Medical Sciences；Department of Medical Oncology，Harbin Medical University Cancer Hospital；Department of Gastroenterology，Affiliated Tumor Hospital，Xinjiang Medical University；Department of Thoracic Surgical Oncology，National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital，Chinese Academy of Medical Sciences and Peking Union Medical College）.The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma[J].Cancer Biology & Medicine,2021,第2期 Meina Jiang^1,2，Shuai Fang^1,2，Xiaodong Zhao^1,3，Chengwei Zhou^1,3，Zhaohui Gong^1,2（Department of Biochemistry and Molecular Biology，Ningbo University School of Medicine；Zhejiang Province Key Laboratory of Pathophysiology，Ningbo University School of Medicine；Department of Thoracic Surgery，The Affiliated Hospital of Ningbo University School of Medicine）.Epithelial-mesenchymal transition-related circular RNAs in lung carcinoma[J].Cancer Biology & Medicine,2021,第2期 Qiujuan Huang¹，Tongyuan Qu¹，Lisha Qi¹，Changxu Liu²，Yuhong Guo¹，Qianru Guo¹，Guangning Li¹，Yalei Wang¹，Wenshuai Zhang¹，Wei Zhao¹，Danyang Ren¹，Leina Sun¹，Shengguang Wang³，Bin Meng¹，Baocun Sun¹，Bin Zhang⁴，Wenjuan Ma⁵，Wenfeng Cao¹（Department of Pathology，Tianjin Medical University Cancer Institute and Hospital，National Clinical Research Center for Cancer，Key Laboratory of Cancer Prevention and Therapy，Tianjin，Tianjin’s Clinical Research Center for Cancer；Department of Pathology，Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital；Department of Lung Cancer，Tianjin Lung Cancer Center；Department of Breast Cancer；Department of Breast Imaging，Key Laboratory of Breast Cancer Prevention and Therapy，Tianjin Medical University Cancer Institute and Hospital，National Clinical Research Center for Cancer，Key Laboratory of Cancer Prevention and Therapy，Tianjin，Tianjin’s Clinical Research Center for Cancer）.A nomogram-based immune-serum scoring system predicts overall survival in patients with lung adenocarcinoma[J].Cancer Biology & Medicine,2021,第2期 Jie Liang^1,2，Xiao Zhao^1,2（CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety & CAS Center for Excellence in Nanoscience，National Center for Nanoscience and Technology of China；University of Chinese Academy of Sciences）.Nanomaterial-based delivery vehicles for therapeutic cancer vaccine development[J].Cancer Biology & Medicine,2021,第2期 Denise Drago¹，Annapaola Andolfo¹，Ettore Mosca²，Alessandro Orro²，Luigi Nocera³，Vito Cucchiara³，Matteo Bellone⁴，Francesco Montorsi³，Alberto Briganti³（ProMeFa，Proteomics and Metabolomics Facility，Center for Omics Sciences (COSR)，IRCCS San Raffaele Scientific Institute；Institute of Biomedical Technologies，National Research Council (CNR)；Department of Urology and Division of Experimental Oncology，Urological Research Institute (URI)，IRCCS San Raffaele Scientific Institute；Division of Immunology，Transplantation and Infectious Diseases，IRCCS San Raffaele Scientific Institute）.A novel expressed prostatic secretion (EPS)-urine metabolomic signature for the diagnosis of clinically significant prostate cancer[J].Cancer Biology & Medicine,2021,第2期 Li Tu¹，Zheng Luo¹，Yun-Long Wu¹，Shuaidong Huo¹，Xing-Jie Liang²（Fujian Provincial Key Laboratory of Innovative Drug Target Research，School of Pharmaceutical Sciences，Xiamen University；CAS Center for Excellence in Nanoscience，CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety，National Center for Nanoscience and Technology）.Gold-based nanomaterials for the treatment of brain cancer[J].Cancer Biology & Medicine,2021,第2期 Xuan Zhao^1,2，Shasha Liu^1,2，Xinfeng Chen^1,2，Jianyi Zhao³，Feng Li^1,2，Qitai Zhao^1,2，Tan Xie⁴，Lan Huang^1,2，Zhen Zhang^1,2，Yu Qi³，Yang Yang³，Song Zhao³，Yi Zhang^1,2,5,6（Biotherapy Center，The First Affiliated Hospital of Zhengzhou University；Cancer Center，The First Affiliated Hospital of Zhengzhou University；Department of Thoracic Surgery，The First Affiliated Hospital of Zhengzhou University；Department of Pediatric Surgery，The First Affiliated Hospital of Zhengzhou University；School of Life Sciences，Zhengzhou University；Henan Key Laboratory for Tumor Immunology and Biotherapy）.L1CAM overexpression promotes tumor progression through recruitment of regulatory T cells in esophageal carcinoma[J].Cancer Biology & Medicine,2021,第2期首页上一页 1 2 3 下一页尾页共有3页，转到页

期刊文章列表